MarketCap
Celldex Therapeutics CLDX
$ 31.12
0.28%
Facebook
X
Telegram
Celldex Therapeutics ROCE Ratio | CLDX
Annual ROCE Ratio Celldex Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -54.51 | -26.11 | -36.01 | -35.33 | -16.98 | -30.26 | -48.99 | -53.35 | -37.98 | -38.18 | -42.15 | -54.77 | -24.93 | -53.85 | -51.91 | -8.58 | -49.95 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -8.58 | -54.77 | -39.05 |
Quarterly ROCE Ratio Celldex Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -51.84 | -49.48 | -37.6 | -30.99 | -26.09 | -17.17 | -33.88 | -39.21 | -44.25 | -39.4 | -47.42 | -40.68 | -34.55 | -23.83 | -28.6 | -27.95 | -26.55 | -20.71 | -27.56 | -28.22 | -26.99 | -18.42 | -31.02 | -37.21 | -50.86 | -44.71 | -50.97 | -51.98 | -135.41 | -116.33 | -129.85 | -135.83 | -137.08 | -40.61 | -51.91 | -50.59 | -51.8 | -36.94 | -48.1 | -48.09 | -46.58 | -33.13 | -47.46 | -49.79 | -53.38 | -42.7 | -49.98 | -41.48 | -33.43 | -18.55 | -33.95 | -40.76 | -48.8 | -43.36 | -60.06 | -59.04 | -59.01 | -45.13 | -16.7 | -14.38 | -14.05 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -14.05 | -137.08 | -46.27 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ADC Therapeutics SA
ADCT
|
65.38 | $ 1.31 | 6.5 % | $ 166 M |  Schweiz |
 |
ADMA Biologics
ADMA
|
40.11 | $ 9.7 | 3.21 % | $ 2.31 B |  USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-26.11 | $ 27.89 | 0.3 % | $ 4.23 B | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-35.64 | $ 13.3 | 1.06 % | $ 364 M |  Israel |
 |
AbbVie
ABBV
|
-461.01 | $ 265.08 | 0.02 % | $ 469 B | USA |
 |
Axsome Therapeutics
AXSM
|
-188.87 | $ 193.45 | 0.24 % | $ 9.62 B | USA |
 |
Aytu BioScience
AYTU
|
-16.52 | $ 2.28 | 2.24 % | $ 28.1 M | USA |
 |
Adagene
ADAG
|
-60.65 | $ 2.97 | 0.62 % | $ 175 M |  China |
 |
Abeona Therapeutics
ABEO
|
-56.18 | $ 5.53 | 2.65 % | $ 293 M | USA |
 |
Adial Pharmaceuticals
ADIL
|
-147.82 | $ 4.04 | 0.24 % | $ 2.7 M | USA |
 |
Evelo Biosciences
EVLO
|
2172.8 | - | -14.46 % | $ 27.9 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
6.73 | $ 62.21 | 0.06 % | $ 11.9 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-49.83 | $ 4.85 | 0.2 % | $ 929 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 2.16 | 0.45 % | $ 3.56 M | Israel |
 |
Achieve Life Sciences
ACHV
|
-90.77 | $ 7.83 | 0.87 % | $ 341 M | USA |
 |
Catalyst Biosciences
CBIO
|
10.83 | $ 14.19 | 1.17 % | $ 1.27 B | USA |
 |
Amryt Pharma plc
AMYT
|
-5.86 | - | - | $ 621 M |  Britain |
 |
C4 Therapeutics
CCCC
|
-44.91 | $ 3.08 | 0.3 % | $ 255 M | USA |
 |
Codexis
CDXS
|
-82.6 | $ 1.38 | 0.72 % | $ 120 M | USA |
 |
Allakos
ALLK
|
-155.07 | - | - | $ 28.6 M | USA |
 |
Cerus Corporation
CERS
|
-13.52 | $ 2.6 | 4.3 % | $ 496 M | USA |
 |
Coherus BioSciences
CHRS
|
-296.87 | $ 1.26 | 1.48 % | $ 148 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-141.54 | $ 4.04 | 4.94 % | $ 49.3 M | Israel |
 |
AbCellera Biologics
ABCL
|
-16.8 | $ 12.31 | 0.12 % | $ 3.68 B | Canada |
 |
Aclaris Therapeutics
ACRS
|
-74.09 | $ 5.26 | 2.69 % | $ 645 M | USA |
 |
Фармсинтез
LIFE
|
-4.03 | - | - | - |  Russia |
 |
Clovis Oncology
CLVS
|
18.9 | - | -7.23 % | $ 13 M | USA |
 |
Cocrystal Pharma
COCP
|
-120.22 | $ 1.19 | 1.26 % | $ 13.4 M | USA |
 |
Collegium Pharmaceutical
COLL
|
20.14 | $ 22.45 | 1.05 % | $ 711 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
6.92 | $ 112.94 | 3.29 % | $ 11.7 B | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-52.09 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-57.84 | $ 7.74 | 0.19 % | $ 103 M | USA |
 |
Cardiff Oncology
CRDF
|
-107.87 | $ 1.31 | 0.74 % | $ 87.6 M | USA |
 |
Curis
CRIS
|
-104.6 | $ 0.95 | 0.98 % | $ 12.5 M | USA |
 |
CorMedix
CRMD
|
37.04 | $ 7.69 | 0.06 % | $ 554 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-34.58 | $ 55.76 | 1.2 % | $ 5.01 B | Schweiz |
 |
Corvus Pharmaceuticals
CRVS
|
-70.21 | $ 12.54 | 8.21 % | $ 990 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-69.06 | - | - | $ 401 M | USA |
 |
Cue Biopharma
CUE
|
-100.45 | $ 31.71 | 2.62 % | $ 3 B | USA |
 |
CEL-SCI Corporation
CVM
|
-155.48 | $ 1.68 | 0.59 % | $ 13.5 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
92.82 | $ 65.81 | 0.04 % | $ 7.9 M | USA |
 |
Axon Enterprise
AXON
|
-1.91 | $ 450.61 | 1.61 % | $ 35.2 B | USA |
 |
Brickell Biotech
BBI
|
-64.05 | - | -5.38 % | $ 6.06 M | USA |
 |
DiaMedica Therapeutics
DMAC
|
-61.16 | $ 7.56 | 7.16 % | $ 355 M | USA |
 |
Denali Therapeutics
DNLI
|
-54.78 | $ 20.46 | 5.52 % | $ 3.53 B | USA |
 |
Precision BioSciences
DTIL
|
-56.53 | $ 6.36 | 10.62 % | $ 81.6 M | USA |
 |
Dyadic International
DYAI
|
-583.64 | $ 0.41 | 3.72 % | $ 14.8 M | USA |
 |
Editas Medicine
EDIT
|
-586.37 | $ 2.69 | 0.17 % | $ 239 M | USA |
 |
Edesa Biotech
EDSA
|
-63.54 | $ 3.97 | 1.46 % | $ 22.5 M | USA |